Quentin Philippot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8822827/publications.pdf

Version: 2024-02-01

13 5,215 11 13 papers citations h-index g-index

14 14 14 8716
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,983
2	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,749
3	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	5.6	357
4	X-linked recessive TLR7 deficiency in $\sim 1\%$ of men under 60 years old with life-threatening COVID-19. Science Immunology, 2021, 6, .	5.6	267
5	Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature, 2022, 603, 587-598.	13.7	216
6	Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. Journal of Experimental Medicine, 2021, 218, .	4.2	185
7	Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. Journal of Experimental Medicine, 2021, 218, .	4.2	130
8	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200413119.	3.3	110
9	SARS-CoV-2–related MIS-C: A key to the viral and genetic causes of Kawasaki disease?. Journal of Experimental Medicine, 2021, 218, .	4.2	100
10	Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona. Journal of Clinical Immunology, 2021, 41, 1733-1744.	2.0	66
11	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Science Immunology, 2023, 8, .	5.6	35
12	Candidiasis in patients with APS-1: low IL-17, high IFN-Î ³ , or both?. Current Opinion in Immunology, 2021, 72, 318-323.	2.4	8
13	Interstitial lung diseases associated with mutations of poly(A)â€specific ribonuclease: A multicentre retrospective study. Respirology, 2022, 27, 226-235.	1.3	6